I DATI DEL FOURIER (Further Cardiovascular OUtcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk)

Sono stati presentati durante il Congresso Annuale dell’American College of Cardiology, che si sta tenendo a Washinghton in questi giorni, i dati di outcome dello studio FOURIER.

L’articolo pubblicato oggi sul The new journal of medicine :”Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease”

….”In this dedicated cardiovascular outcomes trial, we found that the addition of evolocumab to statin therapy significantly reduced the risk of cardiovascular events, with a 15% reduction in the risk of the primary composite end point of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization and a 20% reduction in the risk of the more clinically serious key secondary end point of cardiovascular death, myocardial infarction, or stroke.”…..